Chemoembolization is a minimally invasive cancer treatment that delivers chemotherapy directly into a tumor’s blood supply while simultaneously blocking the arteries that feed it. This two-pronged approach, often called TACE (transarterial chemoembolization), traps high concentrations of cancer-killing drugs inside the tumor and starves it of oxygen. It is most commonly used to treat liver cancer that cannot be surgically removed.
How Chemoembolization Works
Most liver tumors get their blood supply almost exclusively from the hepatic artery, while healthy liver tissue is fed primarily by the portal vein. Chemoembolization exploits this difference. A doctor threads a thin catheter through a small puncture in the groin artery, guides it up into the liver using real-time X-ray imaging, and positions it as close to the tumor-feeding vessels as possible.
Once in place, the catheter delivers a combination of chemotherapy drugs and tiny particles that physically block blood flow. The blocking particles trap the chemotherapy inside the tumor, keeping drug concentrations far higher than what standard IV chemotherapy could achieve, while limiting how much reaches the rest of the body. At the same time, cutting off the blood supply deprives the tumor of oxygen, which makes the cancer cells even more vulnerable to the drugs.
The goal is to be as selective as possible. Super-selective placement of the catheter into the exact branch feeding the tumor maximizes the effect on cancer cells and minimizes damage to surrounding healthy liver tissue.
Two Main Techniques
There are two primary versions of this procedure. In conventional TACE, chemotherapy drugs are mixed with an oily substance called Lipiodol, which acts as a carrier. The oil delivers the drugs into the tumor’s tiny blood vessels and simultaneously helps block them. Separate particles are then injected to complete the blockage.
The newer approach, called drug-eluting bead TACE (DEB-TACE), uses tiny microspheres that are pre-loaded with chemotherapy. These beads serve double duty: they slowly release the drug over time while also physically plugging the tumor’s blood supply. This method was designed to provide a more controlled, sustained release of medication compared to the conventional technique.
Who Is a Candidate
Chemoembolization is the most widely used palliative treatment for hepatocellular carcinoma, the most common form of primary liver cancer. Current guidelines recommend it as the first-line non-surgical therapy for patients who have tumors that cannot be removed with surgery, have not invaded major blood vessels, and have not spread beyond the liver. Typical candidates have either a single tumor larger than 3 centimeters or multiple tumors, with reasonably preserved liver function and no significant cancer-related symptoms.
Liver function is the critical factor in determining eligibility. Patients with severely impaired liver function, signs of end-stage cirrhosis (such as fluid buildup in the abdomen, jaundice, or confusion from liver-related brain effects), or bilirubin levels above a certain threshold are generally not candidates. The procedure relies on the healthy portion of the liver continuing to function normally through its separate blood supply, so if the liver is already failing, the risks outweigh the benefits.
What the Procedure Feels Like
Chemoembolization is performed under sedation, not general anesthesia. You stay in the hospital, typically overnight. The catheter insertion site in the groin is numbed with local anesthetic, and you may feel pressure or warmth as the chemotherapy mixture is delivered. The entire procedure usually takes one to two hours, depending on how many tumors are being treated and how complex the blood vessel anatomy is.
Most patients undergo more than one session. Treatments are spaced weeks apart, and imaging scans between sessions help doctors assess how the tumor is responding and whether additional rounds are needed.
Recovery and Side Effects
Recovery typically takes 7 to 10 days. After discharge, you should rest and avoid heavy lifting (anything over 10 pounds) for three days. Driving is off-limits for the first 24 hours. Most people can begin resuming normal activities the day after leaving the hospital and gradually increase physical activity over the following week.
The most common side effect is post-embolization syndrome, which the majority of patients experience to some degree. It involves pain or cramping near the treatment site, low-grade fever, nausea, fatigue, and loss of appetite. Pain tends to be worst in the first two to three hours after the procedure and stays fairly constant for about 12 hours before gradually easing. Fever, nausea, and fatigue can peak around two to three days later and then taper off. The syndrome is uncomfortable but expected, and pain management is a standard part of post-procedure care.
How Effective Is Chemoembolization
Chemoembolization is a palliative treatment, meaning it aims to control the cancer and extend life rather than cure it. Outcomes vary widely depending on liver function, tumor size, and how many tumors are present. A six-year follow-up study of liver cancer patients treated with TACE found one-year survival of 58%, two-year survival of about 24%, and three-year survival around 8%. These numbers reflect a broad patient population, and individual outcomes depend heavily on the stage of disease at treatment and overall liver health.
The procedure is often used as a bridge strategy for patients waiting for a liver transplant, keeping the cancer in check until a donor organ becomes available. It can also be combined with other treatments, including targeted drug therapies, to improve results.
Chemoembolization vs. Radioembolization
A closely related alternative is radioembolization (sometimes called Y-90), which uses the same catheter-based approach but delivers tiny radioactive beads instead of chemotherapy drugs. The beads lodge in the tumor’s blood vessels and kill cancer cells with targeted radiation rather than chemical toxins.
A systematic review and meta-analysis comparing the two found that one-year survival rates were virtually identical. However, radioembolization showed a meaningful advantage in slowing tumor progression: one-year progression-free survival was significantly better with Y-90. Longer-term data also trended in favor of radioembolization, with statistically better two-year and three-year survival rates. Radioembolization produces disease control rates above 80% and tends to be well tolerated, even in patients with blood vessel involvement that might disqualify them from TACE.
Despite these differences, no definitive evidence yet establishes one technique as clearly superior for overall survival. The choice between them often comes down to individual factors: tumor location, blood vessel anatomy, liver function, and what’s available at your treatment center.